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Abstract Interstitial pneumonitis is a classical complica-
tion of many drugs. Pulmonary toxicity due to 5-azacy-
tidine, a deoxyribonucleic acid methyltransferase inhibitor
and cytotoxic drug, has rarely been reported. We report a
67-year-old female myelodysplastic syndrome patient
treated with 5-azacytidine at the conventional dosage of
75 mg/m2 for 7 days. One week after starting she devel-
oped moderate fever along with dry cough and subse-
quently her temperature rose to 39.5 C. She was placed
under broad-spectrum antibiotics based on the protocol for
febrile neutropenia, including ciprofloxacin 750 mg twice
daily, ceftazidime 1 g three times daily (tid), and sul-
famethoxazole/trimethoprim 400 mg/80 mg tid. High-res-
olution computed tomography of the chest disclosed
diffuse bilateral opacities with ground-glass shadowing and
pleural effusion bilaterally. Mediastinal and hilar lymph
nodes were moderately enlarged. polymerase chain reac-
tion for Mycobacterium tuberculosis, Pneumocystis jir-
oveci, and cytomegalovirus were negative. Cultures
including viral and fungal were all negative. A diagnosis of
drug-induced pneumonitis was considered and, given the
negative bronchoalveolar lavage in terms of an infection,
corticosteroid therapy was given at a dose of 1 mg/kg body
weight. Within 4 weeks, the patient became afebrile and
was discharged from hospital. Development of symptoms
with respect to drug administration, unexplained fever,
negative workup for an infection, and marked response to
corticosteroid therapy were found in our case. An expla-
nation could be a delayed type of hypersensitivity (type IV)
with activation of CD8 T cell which could possibly explain
most of the symptoms. We have developed a decision
algorithm in order to anticipate timely diagnosis of
5-azacitidine-induced pneumonitis, and with the aim to
limit antibiotics abuse and to set up emergency treatment.
Key Points
Interstitial pneumonitis is a classical complication of
many drugs.
Pulmonary toxicity due to 5-azacytidine is rarely
mentioned.
It is important to anticipate diagnosis of
5-azacitidine-associated interstitial lung disease to
limit antibiotics abuse and to set up emergency
treatment.
Introduction
Pneumonitis, often called interstitial lung disease or ILD, is
a possible manifestation of many antineoplastic and other
drugs, with several ILD subtypes being described in asso-
ciation with drugs. Pulmonary toxicity from 5-azacytidine,
a deoxyribonucleic acid (DNA) methyltransferase inhibitor
which also exerts cytotoxic effects, has rarely been repor-
ted, although the drug has been used since 1982. 5-Aza-
cytidine acts as a hypomethylating agent of the Y globin
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suppressor gene to induce fetal hemoglobin in thalassemia
and, since 2000, to treat high-risk myelodysplastic syn-
drome (MDS) and acute myelogenous leukemia (AML)
with low blast counts. Here, we report a case of 5-azacy-
tidine-asociated pneumonitis, review the literature, and
develop a diagnostic algorithm for this rare condition to
avoid delay in medical care and misuse of antibiotics.
Case Report
A 67-year-old woman presented as an outpatient of our
Hematology Department in August 2015 for progressive
neutropenia, anemia, and fatigue. Peripheral blood exami-
nation showed a normochromic normocytic anemia with
9.4 g/dL hemoglobin, 0.350 9 109/L neutrophils and
138 9 109/L platelets. A bone marrow aspirate (BMA)
showed hypercellular marrow with trilineage dysplastic
features, micromegakaryocytes and 13% myeloblasts. A
diagnosis of refractory cytopenia with multilineage dys-
plasia was given, based on the WHO MDS classification
[1]. A trephine biopsy was in accordance with the results
from the bone marrow aspirate with 15% myeloblasts
displaying dyserythropoiesis and dysmegakaryopoiesis.
Karyotype G banding analysis revealed a complex
cytogenetic abnormality: 46,XX,del(5)(q14q34) [2]/
49,sl,?1,?9,?11 [2]/52,sd1,?11,?22,?22 [16].
Based on the above data, high-risk MDS was considered.
The patient underwent appropriate tests concerning eligi-
bility for allogenic stem cell transplantation. She received
the first cycle of 5-azacytidine at the conventional dosage of
75 mg/m2 for 7 days from September 28, 2015. One week
after starting 5-azacytidine, she developed moderate fever
along with dry cough and, subsequently, her temperature
rose to 39.5 C. She was hospitalized on October 11, 2015.
Vital signs and pulse oximetry were normal. She was placed
under broad-spectrum antibiotics based on the protocol for
febrile neutropenia, including ciprofloxacin 750 mg twice
daily, ceftazidime 1 g three times daily (tid), and sul-
famethoxazole/trimethoprim 400 mg/80 mg tid. Fever did
not abate. All routine bacteriological investigations were
negative. Procalcitonin levels were within the normal range.
The chest and sinus radiographs were normal, as were pre-
cipitins against Aspergillus and titers against Cy-
tomegalovirus (CMV) and Epstein-Barr virus (EBV). CMV
antigenemia was negative. An interferon-c release assay was
negative. Marrow re-aspiration revealed a 22% increment of
blast number, suggesting a transformation towards acute
myeloid leukemia. During her second week in hospital, the
patient complained of dyspnea on October 22, 2015. Blood
gas showed a PaO2 of 59 mmHg and PaCO2 of 29 mmHg.
Pulse oxygen saturation was 91% (room air). High-resolu-
tion computed tomography (HRCT) of the chest disclosed
diffuse bilateral opacities with ground-glass shadowing and
pleural effusion bilaterally (Fig. 1). Mediastinal and hilar
lymph nodes were moderately enlarged. The patient was
transferred to the intensive care unit on October 23 for
bronchoalveolar lavage (BAL), which showed 170 red blood
cells/mm3 and 10 white blood cells/mm3. Polymerase chain
reaction (PCR) for Mycobacterium tuberculosis, Pneumo-
cystis jiroveci, and CMV were negative. Immunofluores-
cence test for Pneumocystis was also negative. Cultures
including viral and fungal were all negative. The patient was
maintained on antibiotics. A diagnosis of drug-induced
pneumonitis was considered and, given the negative BAL in
terms of an infection, corticosteroid therapy was given at a
dose of 1 mg/kg bodyweight onOctober 28.Within 4 days, a
significant improvement in clinical status and imaging was
noted. A repeat chest computed tomography (CT) scan at 1
week also showed significant improvement. Temperature
was normal and C-reactive protein returned to normal within
1 week. Following 2 days of quick steroid tapering, the
patient again developed fever. Left upper chest pain corre-
sponding to lobulated pleural effusion was noted and
1200 mL of serosanguinous fluid was removed via chest
tube. Pleural fluid was a predominantly neutrophilic exudate
containing 4 g/dL proteins. Corticosteroids weremaintained
and antibiotics were discontinued. The patient remained
afebrile and was discharged from hospital on November 9.
She eventually received a haploidentical bone marrow
transplant on December 23, 2015.
Discussion
Clinical features of 5-azacytidine-associated ILD include
cough, dyspnea, pleuritic chest pain, and hypoxemic res-
piratory failure [2]. Like many antineoplastic agent-in-
duced lung diseases, prominent imaging findings include
Fig. 1 High-resolution computed tomography of the chest disclosed
diffuse bilateral interstitial opacities with ground-glass shadowing,
and pleural effusion bilaterally
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diffuse multifocal ground-glass shadowing, interstitial
thickening, and pleural effusion.
Here we review 12 earlier cases of 5-azacytidine-asso-
ciated pneumonitis (Table 1). Delayed diagnosis following
failure of broad-spectrum antibiotic therapy was common
[3–14]. Corticosteroids were used depending on severity.
The diagnosis of drug-induced pneumonitis rests on
history of drug exposure, clinical imaging, bronchoalveolar
lavage, exclusion of other lung conditions, improvement
following drug discontinuation, and recurrence of symp-
toms upon rechallenge with the drug. In the present case,
we were reluctant to readminister the drug as the risk of
doing so is poorly known. The Naranjo probability score in
this case was 6, consistent with probable adverse reaction
[15, 16]. In our case, despite steroid use, symptoms
relapsed and were characterized as serosanguinous pleural
effusion. Serosanguinous pleural exudates with polymor-
phonuclear leukocyte predominance without
Neutropenic fever
Piperacillin/tazobactam or meropenem
(routine blood urine CXR) CRP
Does not subside
Subsides
CXR characteristic finding and/or 
dyspnea
ANA and p-ANCA antibodies dosing
1. Imipenem/cilastatin or meropenem
2. Ag aspergillus, CMV EBV PCR, 
quantiferon pneumococcal, βDglucan
3. CT scan + BAL
Specific radiologic
signs : aspergillus, 
CMV
Signs of interstitial pneumonitis
Pleural effusion
Ground glass opacities without cavity
BAL negative :
cytology, gram stain, immonufluorescence
1. Corticosteroid methylprednisolone 1-2 mg/kg
2. Antibiotic coverage as per advice of pulmonary or infectiology
consultant
Repeat bacteriological test





Refer nearest pulmonary referent center
BAL positive : 




























Fig. 2 Decision algorithm for 5-azacitidine-induced ILD
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bacteriological evidence of infection may be a manifesta-
tion of pleurisy such as in lupus erythematosus, which
might be induced by the drug in question [17].
Mechanisms for drug-induced ILD are direct cytotoxi-
city, hypersensitivity, oxidative stress, release of cytokines
and thus pyrogens, and lastly impaired repair by type II
pneumocytes. Chronology of events, unexplained fever,
and steroid response to clinical and radiological signs
constitute a hypersensitivity pneumonitis.
5-Azacytidine is a cytosine analog, a potent inhibitor of
DNA methyltransferase, with a hypomethylating effect
in vivo and in vitro. Unlike gemcitabine, although cyto-
toxic at high dose, at low dose it is capable of inducing
differentiation and hypomethylation. Hence, profound
myelosuppression or direct lung injury like capillary leak
syndrome is not encountered during 5-azacytidine toxicity.
The role of oxidative stress is still unclear although there
are a few reports concerning induction of necrosis in vitro
by 5-azacytidine [18]. Oxidative stress could contribute to
T-cell response by inhibiting the ERK pathway signaling in
T cells. Recently we observed drug-associated ILD in two
patients treated with an experimental inhibitor of DNA
methyltransferase, suggesting a common class effect
[19, 20].
Unlike oxaliplatin, anaphylactic reaction is extremely
rare in 5-azacytidine. Few patients develop symptoms
during the administration of chemotherapy. Although an
elevated IgE level was reported in one case by Nair et al.,
the evidence is not sufficient to conclude a type I reaction
[8]. Most patients develop symptoms within a week to a
month after administration of 5-azacytidine. Although the
histopathological evidence is rarely possible in immuno-
compromised patients with hematological malignancy,
Sekhri et al. presented a bronchocentric granuloma in their
report [7]. Hence, another plausible explanation could be a
delayed type of hypersensitivity (type IV) with activation
of CD8 T cell, which could explain most of the symptoms.
This could possibly occur during a relative immune
reconstitution phase of an immunocompromised patient.
The pulmonary fibrosis may be due to DNA
hypomethylation causing direct upregulation of type I
collagen synthesis. Sanders et al. suggested that the DNA
methylation is important in idiopathic pulmonary fibrosis
(IPF), as an altered DNA methylation profile has been
demonstrated in their experiment [21]. Moreover, there are
reports suggesting the epigenetic priming by 5-azacytidine
confers transdifferentiating properties to various cells.
However, it is difficult to establish a relationship at present
[22].
Our diagnostic algorithm is based on that of drug-in-
duced interstitial lung disease (DILD), and is not specific
for 5-azacytidine (Fig. 2). Any febrile condition in those
patients with worsening pulmonary symptoms despite
broad-spectrum antibiotics should arouse suspicion of
DILD. HRCT and BAL are crucial as 5-azacytidine-in-
duced pneumonitis remains a diagnosis of exclusion, like
many other DILDs. Some nonspecific immunological tests
could be helpful, like levels of p-ANCA (antineutrophil
cytoplasmic antibody) and ANA (antinuclear antibody).
Prompt consultation with a pulmonary care unit is of
utmost utility.
Conclusions
A high degree of vigilance is advised to entertain the
diagnosis in a timely manner, since the condition can be
fatal. We now utilize a decision algorithm in order for
timely diagnosis of 5-azacitidine-induced ILD to limit
antibiotics abuse and to set up emergency treatment.
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